Dr. Benedito Carneiro is a medical oncologist and clinical investigator specializing in early-phase clinical trials and novel therapeutics for solid tumors and genitourinary cancers. He has led the expansion of the Cancer Drug Development Program (Phase I) at Brown and the Lifespan Cancer Institute, significantly increasing patient access to first-in-human studies in Rhode Island.

His research focuses on innovative immunotherapies, genomic-driven treatment strategies, cellular therapies, and biomarkers of response and resistance. Dr. Carneiro has been a Principal Investigator or Co-Investigator on more than 120 clinical trials and has authored over 110 peer-reviewed publications.

Before joining Brown, he co-directed the Developmental Therapeutics Program at the Lurie Comprehensive Cancer Center, Northwestern University, where he also directed the postgraduate Developmental Therapeutics Fellowship Program. He is an active member of ASCO, AACR, and ESMO, and represents the Legorreta Cancer Center in the Worldwide Innovative Networking in Personalized Cancer Medicine (WIN) Consortium.

Translational Research Disease Groups (TRDGs) provide a regular forum for advancing translational cancer research and fostering collaboration across disciplines. Eight TRDGs have been established at the Legorreta Cancer Center, each organized around a specific cancer type.

The Genitourinary Cancer TRDG brings together a multidisciplinary team of researchers and clinicians, including experts in:

• Hematology/oncology, radiation oncology, and surgical oncology
• Pathology, cancer biology, genetics, population science, biostatistics, and bioinformatics
• Fellows, residents, and student trainees

Our meetings create opportunities to:

• Develop and prioritize new translational research directions
• Share resources and expertise across Brown and affiliated hospitals
• Launch collaborations that can lead to pilot funding, extramural grant applications, and publications in high-impact journals
• Advance investigator-initiated clinical trials and translational protocols

TRDGs meet every 2–3 months, typically at the Brown University Molecular Medicine Building (70 Ship Street) or at an affiliated hospital site. Meetings feature a mix of roundtable discussions and designated speakers, with ample time for feedback and collaborative planning. Minutes are shared internally with group members.

Membership is open and evolving. We welcome faculty, fellows, residents, and students with an interest in translational breast cancer research to join our efforts.

• Review ongoing translational research and investigator-initiated trials
• Identify collaboration opportunities based on current science and feasibility
• Discuss biomarkers, tumor signaling pathways, and drug development strategies
• Exchange information on funding opportunities (e.g., P01s, SPOREs, or other translational grants)
• Highlight progress through focused presentations by investigators or subgroups
• Leverage institutional resources (genomics, tissue banks, clinical trial infrastructure, tumor boards)
• Engage trainees and early-career researchers in translational projects
• Form working groups to advance projects toward new protocols, grant submissions, and publications

Contact

For more information or to join the Genitourinary Cancer TRDG, please contact Attila Seyhan, PhD.